SEPPRO Trademark

Trademark Overview


On Thursday, January 29, 2004, a trademark application was filed for SEPPRO with the United States Patent and Trademark Office. The USPTO has given the SEPPRO trademark a serial number of 78359775. The federal status of this trademark filing is REGISTERED AND RENEWED as of Tuesday, September 22, 2015. This trademark is owned by GenWay Biotech, Inc.. The SEPPRO trademark is filed in the Chemical Products and Computer & Software Services & Scientific Services categories with the following description:

Reagents for fractionating target proteins from complex biological fluids, such as plasma, serum, CSF, urine or other tissue or cellular sources, and the subsequent chemical analysis of compounds physiologically associated with abundant proteins including proteins, peptides, fatty acids, hormones, glycosylation states, phosphorylation states, etc; Reagents for diagnosis of diseases associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Immunoaffinity reagents for developing chemical markers that indicate the presence of disease states associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Reagents for determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the d...

Product development, medical and laboratory research in the field of proteomics, namely the science, system, components, organization, function, and biomedical applications of separation of abundant proteins, especially, in the area of proteomics sample processing that permits highly selective separation of abundant proteins, such as albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; development of chemical markers that indicate the presence of disease states; determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions in humans and animals; determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets; developing methodologies relating to the previous services such as developing bioanalytical method...
seppro

General Information


Serial Number78359775
Word MarkSEPPRO
Filing DateThursday, January 29, 2004
Status800 - REGISTERED AND RENEWED
Status DateTuesday, September 22, 2015
Registration Number3007344
Registration DateTuesday, October 18, 2005
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 26, 2005

Trademark Statements


Goods and ServicesReagents for fractionating target proteins from complex biological fluids, such as plasma, serum, CSF, urine or other tissue or cellular sources, and the subsequent chemical analysis of compounds physiologically associated with abundant proteins including proteins, peptides, fatty acids, hormones, glycosylation states, phosphorylation states, etc; Reagents for diagnosis of diseases associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Immunoaffinity reagents for developing chemical markers that indicate the presence of disease states associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Reagents for determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions related to albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3 and associated compounds in humans and animals; Reagents for determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3, all for research use
Goods and ServicesProduct development, medical and laboratory research in the field of proteomics, namely the science, system, components, organization, function, and biomedical applications of separation of abundant proteins, especially, in the area of proteomics sample processing that permits highly selective separation of abundant proteins, such as albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; development of chemical markers that indicate the presence of disease states; determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions in humans and animals; determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets; developing methodologies relating to the previous services such as developing bioanalytical methods to increase sensitivity, specificity and throughput of identifying and characterizing biological substances such as protein, peptides, hormones, lipids, used as biomarkers for a diagnosis or as drug targets

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateWednesday, December 8, 2004
Primary Code001
First Use Anywhere DateWednesday, January 28, 2004
First Use In Commerce DateWednesday, January 28, 2004

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, February 9, 2004
Primary Code042
First Use Anywhere DateWednesday, January 28, 2004
First Use In Commerce DateWednesday, January 28, 2004

Trademark Owner History


Party NameMERCK KGAA
Party Type33 - New Owner After Registration
Legal Entity Type31 - NOT AVAILABLE
AddressDARMSTADT 64293
DE

Party NameSIGMA-ALDRICH CO., LLC
Party Type32 - New Owner After Registration
Legal Entity Type16 - Limited Liability Company
AddressST. LOUIS, MO 63103

Party NameSIGMA-ALDRICH BIOTECHNOLOGY L.P.
Party Type31 - New Owner After Registration
Legal Entity Type13 - Limited Partnership
AddressST. LOUIS, MO 63103

Party NameGenWay Biotech, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 921211643

Party NameGenWay Biotech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 921211643

Party NameGenWay Biotech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 921211643

Trademark Events


Event DateEvent Description
Thursday, May 20, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, May 20, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 20, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, May 20, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 20, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 20, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, October 28, 2020AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, September 22, 2015NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Tuesday, September 22, 2015REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, September 22, 2015REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, September 22, 2015CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, August 24, 2015TEAS SECTION 8 & 9 RECEIVED
Monday, August 24, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, April 21, 2012NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Saturday, April 21, 2012REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Saturday, April 21, 2012CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, April 9, 2012TEAS SECTION 8 & 15 RECEIVED
Tuesday, October 4, 2011ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, October 4, 2011TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 14, 2011ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, March 11, 2009AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, October 18, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, July 26, 2005PUBLISHED FOR OPPOSITION
Wednesday, July 6, 2005NOTICE OF PUBLICATION
Thursday, May 26, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, May 23, 2005ASSIGNED TO LIE
Friday, May 13, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 13, 2005EXAMINERS AMENDMENT E-MAILED
Friday, May 13, 2005EXAMINERS AMENDMENT -WRITTEN
Wednesday, May 11, 2005PREVIOUS ALLOWANCE COUNT WITHDRAWN
Friday, April 22, 2005WITHDRAWN BEFORE PUBLICATION
Thursday, January 27, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, January 25, 2005ASSIGNED TO LIE
Tuesday, January 11, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 10, 2005EXAMINERS AMENDMENT E-MAILED
Monday, January 10, 2005EXAMINERS AMENDMENT -WRITTEN
Wednesday, December 8, 2004AMENDMENT FROM APPLICANT ENTERED
Wednesday, December 1, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 1, 2004TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 26, 2004NON-FINAL ACTION E-MAILED
Friday, August 20, 2004ASSIGNED TO EXAMINER
Monday, February 9, 2004NEW APPLICATION ENTERED IN TRAM